(Date:11/8/2009)...ssage of Health Care Reform Bill ,, Critical ...erage for all Americans ,, BALTIMORE, Nov. 7 /...nited States House of Representatives passed criti...ngthen Medicare for seniors and end discrimination...ericans out of affordable health coverage. ,, T...
(Date:11/7/2009)...Newswire-USNewswire/ -- Karen Ignagni, President a... released the following statement today on House p...support comprehensive health care reform, and we h...complete overhaul of how health insurance is provi...erage, elimination of pre-existing condition exclu...
(Date:11/7/2009)...wswire-USNewswire/ -- The American Medical Associa...ard for Citizenship and Community Service to Manus...IL. The award recognizes physicians who have gone ...o make an outstanding public service contribution ...ward today during the opening session of the 2009 ...
(Date:11/7/2009)...(CT), David A. Cook (GA), Louis J. Goodman (TX), P... ,, CHICAGO, Nov. 7 ...nted five medical society executive leaders with a...the goals and ideals of the medical profession. Th...olicy making meeting in Houston. ,, (Logo: h...
(Date:11/7/2009)...swire-USNewswire/ -- Members of the AMA are trying...solution rescinding the AMA,s support of HR 3962. ... responsible to their PATIENTS, not the leadership...icy for the Association of American Physicians and...other medical groups. ,, "If the AMA leadershi...
Breaking Medicine News(10 mins):Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2Health News:AMA Honors Medical Society Executives 2...m cells and their more committed kin, progenitor c...ability to produce different types of specialized ...r or replace damaged tissue holds great promise f...genitor cell? A team of researchers led by Berkele...
...., Feb. 27 Zimmer Holdings, Inc. (NYSE: ZMH ; S...utive Vice President and Chief Operating Officer o...d to its Board of Directors. Thermo Fisher Scient...are, and environmental, industrial and safety mark...
...rs note that exact in-flight medical emergency num...lthDay News) -- More than half of the medical emer...nting, a new study shows, but the researchers note...y data from 32 European airlines, although only fo...
...N, China, Feb. 27 /PRNewswire-Asia/ -- Winner Medi...Medical", the "Company"), a leading,manufacturer i...nd wound care,products), today announced that the ...by the patent: method for producing,spunlace non-w...
...h in Annual Net Sales Driven by Demand for Branded...m Operations, up 25% from 2007 , , - Provides 200..., CHADDS FORD, Pa., Feb. 27 Endo Pharmaceuticals ...ear ended December 31, 2008. , , Net sales for t...
..., ON, Feb. 27 /PRNewswire-FirstCall/ - Nuvo Resear...mpany focused on the research and development of d... skin using its topical and transdermal drug deliv...porate Developments:, - Presented positive Ph...
Other Medicine News:Health News:Cell microenvironments hold key to future stem cell therapies 2Health News:Cell microenvironments hold key to future stem cell therapies 3Health News:Cell microenvironments hold key to future stem cell therapies 4Health News:Cell microenvironments hold key to future stem cell therapies 5Health News:Zimmer Holdings Names Marc Casper to Board of Directors 2Health News:Zimmer Holdings Names Marc Casper to Board of Directors 3Health News:Fainting Most Common Medical Crisis on Planes 2Health News:Fainting Most Common Medical Crisis on Planes 3Health News:Fainting Most Common Medical Crisis on Planes 4Health News:Winner Medical Receives European Patent Office Approval for PurCotton(TM) Production Method 2Health News:Winner Medical Receives European Patent Office Approval for PurCotton(TM) Production Method 3Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 3Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 4Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 5Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 6Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 7Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 8Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 9Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 10Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 11Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 12Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 13Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 14Health News:Nuvo announces 2008 fourth quarter and year-end financial results 2Health News:Nuvo announces 2008 fourth quarter and year-end financial results 3Health News:Nuvo announces 2008 fourth quarter and year-end financial results 4Health News:Nuvo announces 2008 fourth quarter and year-end financial results 5Health News:Nuvo announces 2008 fourth quarter and year-end financial results 6Health News:Nuvo announces 2008 fourth quarter and year-end financial results 7Health News:Nuvo announces 2008 fourth quarter and year-end financial results 8Health News:Nuvo announces 2008 fourth quarter and year-end financial results 9Health News:Nuvo announces 2008 fourth quarter and year-end financial results 10Health News:Nuvo announces 2008 fourth quarter and year-end financial results 11Health News:Nuvo announces 2008 fourth quarter and year-end financial results 12.../ -- Sugammadex -,the novel selective relaxant bin...human healthcare business unit of Akzo Nobel -,dem...s faster,reversal of neuromuscular blockade as com...rative residual curarization (PORC) or,re-occurren...s,pivotal Aurora trial were presented today at the...
...7 - Geron,Corporation,s (Nasdaq:GERN) telomerase i...od pharmacokinetics and tolerability in,its ongoin...,lymphocytic leukemia (CLL), according to data pre...ompany,s president, oncology, at,the Pan Pacific L...rmacokinetics; Pharmacodynamics Consistent with,Ex...
Other Medicine Technology:Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine 2Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine 3Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine 4Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 2Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 3Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 4